Skip to main content
NCBI home page
Autoimmunity Highlights logoLink to Autoimmunity Highlights
. 2010 Nov 4;1(2):87–94. doi: 10.1007/s13317-010-0013-5

Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab

Martina Fabris 1,✉, Salvatore De Vita 3, Nadia Blasone 2, Daniela Visentini 2, Elena Pezzarini 2, Elena Pontarini 3, Cinzia Fabro 3, Luca Quartuccio 3, Saulle Mazzolini 1, Francesco Curcio 1, Elio Tonutti 2
PMCID: PMC4389048  PMID: 26000112

Abstract

Rheumatoid arthritis (RA) is characterized by the presence of circulating rheumatoid factor (RF) and anticitrullinated peptide antibodies (ACPA), which are positive in about 70–80% of patients. APCA have a higher specificity and therefore a higher diagnostic power than RF, but are less informative than RF in monitoring the course of the disease in patients under treatment. Recently, it has been reported that the anticitrullinated vimentin (a-MCV) antibody test can identify a particular subgroup of APCA that may be negative for anticyclic citrullinated peptide (a-CCP) antibodies. Concerning RF, the RF IgA isotype has been described as a more specific marker of erosive joint damage than total RF. The aim of our study was to monitor the levels of a-CCP, a-MCV, total RF and RF IgA in the follow-up of patients with RA treated with B-lymphocytedepletive rituximab (RTX), to detect any differences or peculiarities in patterns of these autoantibodies, especially in relation to their potential use as predictive markers of therapeutic response. We studied 30 patients with RA treated with RTX. All patients were previously unresponsive to at least 6 months of therapy with disease-modifying antirheumatic drugs (DMARDs; methotrexate, leflunomide, cyclosporine, chloroquine) and/or at least 6 months of therapy with anti-TNF biologics. The evaluation of response to RTX was made at month +6 using the EULAR criteria (DAS28). a-CCP, a-MCV, total RF and RF IgA were determined at baseline (before the first infusion of RTX) and after 1, 3 and 6 months. In serum samples obtained before treatment two cytokines essential for Blymphocyte proliferation, interleukin 6 (IL-6) and B-lymphocyte stimulator (BLyS) were also determined. In all patients a significant and consistent reduction in all the tested antibodies was found during follow-up, with no differences in respect of the degree of response to RTX. Of note, at baseline, generally a higher titre of all autoantibodies was seen in patients who then showed a better response to RTX. Finally, there were no differences in serum concentrations of IL-6 and BLyS in patients in relation to the presence or absence of the autoantibodies investigated, nor was there any significant correlation between the serum concentrations of the cytokines and the titres of the autoantibodies. Thus, neither a-MCV compared to a- CCP, nor RF IgA compared to routine total RF, provided any additional predictive information in the follow-up of patients with RA treated with RTX.

Keywords: Anticitrullinated peptide antibodies, Antimodified citrullinated vimentin antibodies, Rheumatoid factor, Rheumatoid arthritis, Rituximab

References

  • 1.De Vita S., Zaja F., Sacco S., et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002;46:2029–2033. doi: 10.1002/art.10467. [DOI] [PubMed] [Google Scholar]
  • 2.Edwards J.C., Leandro M.J., Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans. 2002;30:824–828. doi: 10.1042/bst0300824. [DOI] [PubMed] [Google Scholar]
  • 3.Leandro M.J., Edwards J.C., Cambridge G., et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673–2677. doi: 10.1002/art.10541. [DOI] [PubMed] [Google Scholar]
  • 4.Meijer J.M., Pijpe J., Vissink A., et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009;68:284–285. doi: 10.1136/ard.2008.092601. [DOI] [PubMed] [Google Scholar]
  • 5.De Vita S., Quartuccio L., Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis. 2007;39(Suppl1):S122–S128. doi: 10.1016/S1590-8658(07)80024-7. [DOI] [PubMed] [Google Scholar]
  • 6.Taylor R.P., Lindorfer M.A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20:444–449. doi: 10.1016/j.coi.2008.05.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Maloney D.G., Maloney B., Smith A.R. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(Suppl2):2–9. doi: 10.1053/sonc.2002.30156. [DOI] [PubMed] [Google Scholar]
  • 8.Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659–1669. doi: 10.1084/jem.20040119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Szodoray P., Alex P., Dandapani V., et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol. 2004;60:209–218. doi: 10.1111/j.0300-9475.2004.01441.x. [DOI] [PubMed] [Google Scholar]
  • 10.Rehnberg M., Amu S., Tarkowski A., et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11:R123. doi: 10.1186/ar2789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ziswiler H.R., Aeberli D., Villiger P.M., Möller B. High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:939–943. doi: 10.1093/rheumatology/kep139. [DOI] [PubMed] [Google Scholar]
  • 12.Wilk E., Witte T., Marquardt N., et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60:3563–3571. doi: 10.1002/art.24998. [DOI] [PubMed] [Google Scholar]
  • 13.Nishimura K., Sugiyama D., Kogata Y., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797–808. doi: 10.7326/0003-4819-146-11-200706050-00008. [DOI] [PubMed] [Google Scholar]
  • 14.Visser H., le Cessie S., Vos K., et al. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46:357–365. doi: 10.1002/art.10117. [DOI] [PubMed] [Google Scholar]
  • 15.Rantapää-Dahlqvist S., de Jong B.A., Berling E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–2749. doi: 10.1002/art.11223. [DOI] [PubMed] [Google Scholar]
  • 16.Kastbom A., Strandberg G., Lindroos A., et al. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the TIRA project) Ann Rheum Dis. 2004;63:1085–1089. doi: 10.1136/ard.2003.016808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Chan M.T., Owen P., Dunphy J., et al. Anti-cyclic citrullinated peptide antibodies are associated with erosive arthritis in SLE. Arthritis Rheum. 2005;52:S611. [Google Scholar]
  • 18.Szodoray P., Szabó Z., Kapitány A., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev. 2010;9:140–143. doi: 10.1016/j.autrev.2009.04.006. [DOI] [PubMed] [Google Scholar]
  • 19.Vallbracht I., Rieber J., Oppermann M., et al. Diagnostic and clinical value of anti-citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 2004;63:1079–1084. doi: 10.1136/ard.2003.019877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bobbio-Pallavicini F., Alpini C., Caporali R., et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004;6:R264–R272. doi: 10.1186/ar1173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Alessandri C., Bombardieri M., Papa N., et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following ant-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 2004;63:1218–1221. doi: 10.1136/ard.2003.014647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bang H., Egerer K., Gauliard A., et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007;56:2503–2511. doi: 10.1002/art.22817. [DOI] [PubMed] [Google Scholar]
  • 23.Snir O., Widhe M., Hermansson M., et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 2010;62:44–52. doi: 10.1002/art.25036. [DOI] [PubMed] [Google Scholar]
  • 24.Mutlu N., Bicakcigil M., Tasan D.A., et al. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J Rheumatol. 2009;36:491–500. doi: 10.3899/jrheum.080656. [DOI] [PubMed] [Google Scholar]
  • 25.Vossenaar R., Despres N., Lapointe E., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6:R142–R150. doi: 10.1186/ar1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Nicaise Roland P., Grootenboer Mignot S., Bruns A., et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther. 2008;10:R142. doi: 10.1186/ar2570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.van der Linden M.P., van der Woude D., Ioan-Facsinay A., et al. Value of anti-modified citrullinated vimentin and thirdgeneration anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum. 2009;60:2232–2241. doi: 10.1002/art.24716. [DOI] [PubMed] [Google Scholar]
  • 28.Qin X, Deng Y, Xu J et al (2010) Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatol Int. DOI: 10.1007/s00296-009-1343-3 [DOI] [PubMed]
  • 29.Luime J.J., Colin E.M., Hazes J.M., Lubberts E. Does antimutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis. 2010;69:337–344. doi: 10.1136/ard.2008.103283. [DOI] [PubMed] [Google Scholar]
  • 30.Mathsson L., Mullazehi M., Wick M.C., et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008;58:36–42. doi: 10.1002/art.23188. [DOI] [PubMed] [Google Scholar]
  • 31.Syversen S.W., Goll G.L., van der Heijde D., et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis. 2010;69:345–351. doi: 10.1136/ard.2009.113092. [DOI] [PubMed] [Google Scholar]
  • 32.Robecchi A., Daneo V. Research on the behaviour, nature and meaning of the rheumatoid factor. Acta Rheumatol Scand. 1959;5:245–262. doi: 10.3109/rhe1.1959.5.issue-1-4.30. [DOI] [PubMed] [Google Scholar]
  • 33.Berling E., Johansonn T., Sundin U., et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65:453–458. doi: 10.1136/ard.2005.041376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bobbio-Pallavicini F., Caporali R., Alpini C., et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007;66:302–307. doi: 10.1136/ard.2006.060608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210. doi: 10.1159/000289205. [DOI] [PubMed] [Google Scholar]
  • 36.Perosa F., Prete M., Racanelli V., Dammacco F. CD20- depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med. 2010;267:260–277. doi: 10.1111/j.1365-2796.2009.02207.x. [DOI] [PubMed] [Google Scholar]
  • 37.Buch M.H. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2010;22:321–329. doi: 10.1097/BOR.0b013e328337bd01. [DOI] [PubMed] [Google Scholar]
  • 38.Benucci M., Li Gobbi F., Sabadini L., et al. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients. Int J Immunopathol Pharmacol. 2009;22:1147–1152. doi: 10.1177/039463200902200434. [DOI] [PubMed] [Google Scholar]
  • 39.Dörner T., Kinnman N., Tak P.P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther. 2010;125:464–475. doi: 10.1016/j.pharmthera.2010.01.001. [DOI] [PubMed] [Google Scholar]
  • 40.Tas S.W. Personalised treatment of arthritis in the next eRA. Neth J Med. 2009;67:362–363. [PubMed] [Google Scholar]
  • 41.Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8(Suppl2):S2. doi: 10.1186/ar1916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mackay F., Mackay C.R. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol. 2002;23:113–115. doi: 10.1016/S1471-4906(01)02159-7. [DOI] [PubMed] [Google Scholar]
  • 43.Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  • 44.van Gaalen F.A., Visser H., Huizinga T.W. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides autoantibody (CCP1 and CCP2) tests for rheumatoid arthritis. Ann Rheum Dis. 2005;64:1510–1512. doi: 10.1136/ard.2004.035089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Bizzaro N., Tonutti E., Tozzoli R., et al. Analytical and diagnostic characteristics of 11 second- and third-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem. 2007;53:1527–1533. doi: 10.1373/clinchem.2007.087569. [DOI] [PubMed] [Google Scholar]
  • 46.Mathsson L., Mullazhei M., Wick M.C., et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008;58:36–45. doi: 10.1002/art.23188. [DOI] [PubMed] [Google Scholar]
  • 47.Damjanovska L., Thabet M.M., Leverht E.W., et al. The diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis. 2010;69:730–732. doi: 10.1136/ard.2009.108456. [DOI] [PubMed] [Google Scholar]
  • 48.De Rycke L., Verhelst X., Kruithof E., et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64:299–302. doi: 10.1136/ard.2004.023523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Thurlings R.M., Vos K., Wijbrandts C.A., et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67:917–925. doi: 10.1136/ard.2007.080960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Quartuccio L., Fabris M., Salvin S., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1557–1559. doi: 10.1093/rheumatology/kep314. [DOI] [PubMed] [Google Scholar]
  • 51.Pyrpasopoulou A., Douma S., Triantafyllou A., et al. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther. 2010;14:43–48. doi: 10.1007/BF03256352. [DOI] [PubMed] [Google Scholar]
  • 52.van Vollenhoven R.F., Chatzidionysiou K., Gabay C., et al. Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA) Ann Rheum Dis. 2009;68(Suppl3):579. [Google Scholar]
  • 53.Bruns A., Nicaise-Roland P., Hayem G., et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anticyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine. 2009;76:248–253. doi: 10.1016/j.jbspin.2008.09.010. [DOI] [PubMed] [Google Scholar]
  • 54.Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis. 2003;62:168–171. doi: 10.1136/ard.62.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Becker-Merok A., Nikolaisen C., Nossent H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15:570–576. doi: 10.1177/0961203306071871. [DOI] [PubMed] [Google Scholar]
  • 56.Fabris M., Quartuccio L., Sacco S., et al. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 2007;46:37–43. doi: 10.1093/rheumatology/kel174. [DOI] [PubMed] [Google Scholar]
  • 57.Tan S.M., Xu D., Roschke V., et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003;48:982–992. doi: 10.1002/art.10860. [DOI] [PubMed] [Google Scholar]

Articles from Auto-Immunity Highlights are provided here courtesy of BMC

RESOURCES